Preclinical pharmacokinetic/pharmacodynamic/efficacy relationships for alisertib, an investigational small-molecule inhibitor of Aurora A kinase

Cancer Chemotherapy and Pharmacology

Volumn 72, Issue 6, 2013, Pages 1255-1264

  Palani, Santhosh ^a   Patel, Mayankbhai ^a   Huck, Jessica ^a   Zhang, Mengkun ^a   Balani, Suresh K ^a   Yang, Johnny ^a   Chen, Susan ^a   Mettetal, Jerome ^a   Manfredi, Mark ^a   Shyu, Wen Chyi ^a   Ecsedy, Jeffrey A ^a   Chakravarty, Arijit ^a  

^a MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

Alisertib; Aurora A kinase; MLN8054; MLN8237; PD biomarkers; PK PD modeling

Indexed keywords

ALISERTIB; ANTINEOPLASTIC AGENT; AURORA A KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL STRAIN HCT116; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INHIBITION; DRUG SCREENING; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IC 50; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; TREATMENT DURATION; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; AURORA KINASE A; AZEPINES; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HCT116 CELLS; HUMANS; INHIBITORY CONCENTRATION 50; MICE; MICE, NUDE; MODELS, BIOLOGICAL; PROTEIN KINASE INHIBITORS; PYRIMIDINES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84890326318     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2305-8     Document Type: Article

References (31)

1. Marumoto T, Honda S, Hara T, Nitta M, Hirota T, Kohmura E, Saya H (2003) Aurora-A kinase maintains the fidelity of early and late mitotic events in HeLa cells. J Biol Chem 278(51):51786-51795
2. Marumoto T, Zhang D, Saya H (2005) Aurora-A - a guardian of poles. Nat Rev Cancer 5(1):42-50
3. Carmena M, Earnshaw WC (2003) The cellular geography of aurora kinases. Nat Rev Mol Cell Biol 4(11):842-854
4. Hirota T, Kunitoku N, Sasayama T, Marumoto T, Zhang D, Nitta M, Hatakeyama K, Saya H (2003) Aurora-A and an interacting activator, the LIM protein Ajuba, are required for mitotic commitment in human cells. Cell 114(5):585-598
5. Huck JJ, Zhang M, McDonald A, Bowman D, Hoar KM, Stringer B, Ecsedy J, Manfredi MG, Hyer ML (2010) MLN8054, an inhibitor of Aurora A kinase, induces senescence in human tumor cells both in vitro and in vivo. Mol Cancer Res 8(3):373-384
6. Manfredi MG, Ecsedy JA, Meetze KA, Balani SK, Burenkova O, Chen W, Galvin KM, Hoar KM, Huck JJ, LeRoy PJ, Ray ET, Sells TB, Stringer B, Stroud SG, Vos TJ, Weatherhead GS, Wysong DR, Zhang M, Bolen JB, Claiborne CF (2007) Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase. Proc Natl Acad Sci USA 104(10):4106-4111
7. Hoar K, Chakravarty A, Rabino C, Wysong D, Bowman D, Roy N, Ecsedy JA (2007) MLN8054, a small-molecule inhibitor of Aurora A, causes spindle pole and chromosome congression defects leading to aneuploidy. Mol Cell Biol 27(12):4513-4525
8. Manfredi MG, Ecsedy JA, Chakravarty A, Silverman L, Zhang M, Hoar KM, Stroud SG, Chen W, Shinde V, Huck JJ, Wysong DR, Janowick DA, Hyer ML, Leroy PJ, Gershman RE, Silva MD, Germanos MS, Bolen JB, Claiborne CF, Sells TB (2011) Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of Aurora A kinase using novel in vivo pharmacodynamic assays. Clin Cancer Res 17(24):7614-7624
9. Cervantes A, Elez E, Roda D, Ecsedy J, Macarulla T, Venkatakrishnan K, Rosello S, Andreu J, Jung J, Sanchis-Garcia JM, Piera A, Blasco I, Manos L, Perez-Fidalgo JA, Fingert H, Baselga J, Tabernero J (2012) Phase I pharmacokinetic/pharmacodynamic study of MLN8237, an investigational, oral, selective Aurora A kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res 18(17):4764-4774
10. Dees EC, Cohen RB, von Mehren M, Stinchcombe TE, Liu H, Venkatakrishnan K, Manfredi M, Fingert H, Burris HA 3rd, Infante JR (2012) Phase I study of Aurora A kinase inhibitor MLN8237 in advanced solid tumors: safety, pharmacokinetics, pharmacodynamics, and bioavailability of two oral formulations. Clin Cancer Res 18(17):4775-4784
11. Macarulla T, Cervantes A, Elez E, Rodriguez-Braun E, Baselga J, Rosello S, Sala G, Blasco I, Danaee H, Lee Y, Ecsedy J, Shinde V, Chakravarty A, Bowman D, Liu H, Eton O, Fingert H, Tabernero J (2010) Phase I study of the selective Aurora A kinase inhibitor MLN8054 in patients with advanced solid tumors: safety, pharmacokinetics, and pharmacodynamics. Mol Cancer Ther 9(10):2844-2852
12. Dees EC, Infante JR, Cohen RB, O'Neil BH, Jones S, von Mehren M, Danaee H, Lee Y, Ecsedy J, Manfredi M, Galvin K, Stringer B, Liu H, Eton O, Fingert H, Burris H (2011) Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors. Cancer Chemother Pharmacol 67(4):945-954
13. Chakravarty A, Shinde V, Tabernero J, Cervantes A, Cohen RB, Dees EC, Burris H, Infante JR, Macarulla T, Elez E, Andreu J, Rodriguez-Braun E, Rosello S, von Mehren M, Meropol NJ, Langer CJ, ON B, Bowman D, Zhang M, Danaee H, Faron-Yowe L, Gray G, Liu H, Pappas J, Silverman L, Simpson C, Stringer B, Tirrell S, Veiby OP, Venkatakrishnan K, Galvin K, Manfredi M, Ecsedy JA (2011) Phase I assessment of new mechanism-based pharmacodynamic biomarkers for MLN8054, a small-molecule inhibitor of Aurora A kinase. Cancer Res 71(3):675-685
14. Mager DE, Wyska E, Jusko WJ (2003) Diversity of mechanism-based pharmacodynamic models. Drug Metab Dispos 31(5):510-518
15. Derendorf H, Meibohm B (1999) Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: concepts and perspectives. Pharm Res 16(2):176-185
16. Wysong DR, Chakravarty A, Hoar K, Ecsedy JA (2009) The inhibition of Aurora A abrogates the mitotic delay induced by microtubule perturbing agents. Cell Cycle 8(6):876-888
17. Sudakin V, Yen TJ (2007) Targeting mitosis for anti-cancer therapy. BioDrugs 21(4):225-233
18. Green MC, Buzdar AU, Smith T, Ibrahim NK, Valero V, Rosales MF, Cristofanilli M, Booser DJ, Pusztai L, Rivera E, Theriault RL, Carter C, Frye D, Hunt KK, Symmans WF, Strom EA, Sahin AA, Sikov W, Hortobagyi GN (2005) Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol 23(25):5983-5992
19. Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T, Wolff AC, Sledge GW Jr, Wood WC, Davidson NE (2008) Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 358(16):1663-1671
20. Furman WL, Stewart CF, Poquette CA, Pratt CB, Santana VM, Zamboni WC, Bowman LC, Ma MK, Hoffer FA, Meyer WH, Pappo AS, Walter AW, Houghton PJ (1999) Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children. J Clin Oncol 17(6):1815-1824
21. Testart-Paillet D, Girard P, You B, Freyer G, Pobel C, Tranchand B (2007) Contribution of modelling chemotherapy-induced hematological toxicity for clinical practice. Crit Rev Oncol Hematol 63(1):1-11
22. Liu Q, Ruderman JV (2006) Aurora A, mitotic entry, and spindle bipolarity. Proc Natl Acad Sci USA 103(15):5811-5816
23. Tyler RK, Shpiro N, Marquez R, Eyers PA (2007) VX-680 inhibits Aurora A and Aurora B kinase activity in human cells. Cell Cycle 6(22):2846-2854
24. Dutertre S, Descamps S, Prigent C (2002) On the role of Aurora-A in centrosome function. Oncogene 21(40):6175-6183
25. Cimini D, Moree B, Canman JC, Salmon ED (2003) Merotelic kinetochore orientation occurs frequently during early mitosis in mammalian tissue cells and error correction is achieved by two different mechanisms. J Cell Sci 116(Pt 20):4213-4225
26. Cimini D (2008) Merotelic kinetochore orientation, aneuploidy, and cancer. Biochim Biophys Acta 1786(1):32-40
27. Cimini D, Wan X, Hirel CB, Salmon ED (2006) Aurora kinase promotes turnover of kinetochore microtubules to reduce chromosome segregation errors. Curr Biol 16(17):1711-1718
28. Thompson SL, Compton DA (2011) Chromosome missegregation in human cells arises through specific types of kinetochore-microtubule attachment errors. Proc Natl Acad Sci USA 108(44):17974-17978
29. Cimini D, Howell B, Maddox P, Khodjakov A, Degrassi F, Salmon ED (2001) Merotelic kinetochore orientation is a major mechanism of aneuploidy in mitotic mammalian tissue cells. J Cell Biol 153(3):517-527
30. Salmon ED, Cimini D, Cameron LA, DeLuca JG (2005) Merotelic kinetochores in mammalian tissue cells. Philos Trans R Soc Lond B Biol Sci 360(1455):553-568
31. Cimini D (2007) Detection and correction of merotelic kinetochore orientation by Aurora B and its partners. Cell Cycle 6(13):1558-1564